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Systemicvasculitiswithprolongedpyrexia,recurrentfacial
urticaria, skin nodules, pleural effusions and venous
thrombosis: an unusual presentation of an uncommon
disease
SystemischeVaskulitismitlangenfieberhaftenZuständen,wiederholter
UrtikariaimGesicht,Hautknötchen,PleuraergussundVenenthrombose:
eine ungewöhnliche Vorstellung einer seltenen Erkrankung
Abstract
Classically presenting with multiple or single peripheral cytopenias of
variable severity, the myelodysplastic syndromes may occasionally
Imad Salah Hassan
1
Javeed Dar
2
present with bizarre manifestations that confuse the clinical picture
and result in significant delays in making the correct diagnosis. We de-
scribe the case of an elderly male patient whose presentation with 1 King Saud ibn Abdulaziz
University for Health prolonged unexplained fever coupled with cutaneous, pulmonary and
Sciences and the othersystemicfeaturesofinflammationwasfinallydiagnosedashaving
Department of Medicine a primary myelodysplastic syndrome with associated vasculitis after a
delay of 4 years. 1443, King Abdulaziz
Medical City, King Fahad
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Das klassische myelodysplastische Syndrom ist gekennzeichnet durch
multipleodervereinzelteCytopenienverschiedenerSchweregrade.Das
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tionen aufweisen, die das klinische Erscheinungsbild ungewöhnlich
verändern und damit die Stellung der korrekten Diagnose wesentlich
verzögern.WirbeschreibendenFalleinesälterenmännlichenPatienten,
der mit langandauernden, unerklärlichen Fieberzuständen zusammen
mit systemischen Entzündungserscheinungen auch an der Haut und in
der Lunge vorgestellt wurde. Nach 4 Jahren Verzögerung wurde die
DiagnoseeinesprimärenmyelodysplastischenSyndromsmitbegleiten-
der Vasculitis gestellt.
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Introduction
The myelodysplastic syndromes (MDS) comprise a heter-
ogeneous group of pre-malignant marrow stem cell dis-
orderscharacterizedbycellulardysplasiaandineffective
erythropoieis associated with increased apoptotic cell
death [1], [2]. These syndromes may arise de novo
(primary) or occur years after exposure to potentially
mutagenictherapy(secondary)e.g.afterradiationexpos-
ure or following cytotoxic chemotherapy [1].
As well as presenting with cytopenias of various degrees
(anemia, bleeding and infections), some patients with
themyelodysplasticsyndromeshaverecentlybeenshown
to develop significant rheumatic and immunological
manifestations [3], [4]. We describe a middle-aged man
whose primary presenting features of an underlying my-
elodysplastic syndrome were related to widespread vas-
culitis namely pyrexia of unknown origin, pneumonitis,
bilateral pleural effusion, recurrent deep venous throm-
bosis, recurrent lobular panniculitis, facial urticaria, and
epididymo-orchitis.
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Case Report OPEN ACCESSCase presentation
Presenting complaints
A 65 year old Caucasian male was admitted acutely
complainingofgenerallyfeelingunwellwithfever,painful
skin swellings over his arms and legs, headache and
epigastric pains.
Past history
Hehadacomplex4yearshistorywhenhepresentedwith
intermittent fever and chills, arthralgia of large joints,
painful skin nodules of arms and legs, dry cough, short-
ness of breath, redness of his right eye, painful right
testicle,anorexiaandweightlossoftwomonthsduration.
He denied oral or genital ulcers. Over the ensuing two
months he was extensively investigated to define the
underlying disease.
Main abnormalities
The main abnormalities on previous investigations were
as follows:
1. Complete blood count: Hemoglobin 106 gram per
litre, mean corpuscular volume (MCV) 97.5, erythro-
cytesedimentationrate(ESR)134mm/Hr,C-reactive
protein (CRP) 135 mg/dl (normal less than 3.5). Nor-
maltotalwhitebloodcell(WBC)countanddifferential.
Rouleoux, oval macrocytes. Pseudo Pelger-Huet cells
and occasional myelocytes on film. Platelet and retic-
ulocyte counts were normal.
2. Liver function test: gamma-glutamyl transferase 172
(7–64iu/l),alkalinephosphatase399(42–121iu/l),
albumin 16 (32–55 iu/l), bilirubin and alanine
aminotransferase normal.
3. Urea 10.2 (3–6 mmol/l), creatinine137 (53–115
umol/l). Normal sodium and potassium.
4. Immunoglobulin (IG) G level was raised (polyclonal)
19.1 (8–18 gm/l). Normal IgM, IgA and IgE levels.
Radiological tests
ChestX-ray:Bilateralpatchybasalconsolidationandmild
bilateral pleural effusions which were confirmed on
computerized tomographic scans.
Ultrasoundscanofscrotalsacshowedchangesconsistent
with epididymo-orchitis.
CT scan of the abdomen: normal.
Serological tests
The following serological tests were done and found to
benegative:HepatitisB&Cscreen,HIVtest,anti-nuclear
antibodies, anti-DNA antibodies, rheumatoid factor, anti-
cytoplasmic antibodies, anti-cardiolipin antibodies,
Coomb's test, ASO titre, cryoglobulins, Brucella serology,
complement levels, C1-esterase level.
Other tests
Other negative tests done for a possible infective agent:
malaria film, Brucella culture, Mantoux test, sputa for
acid fast bacilli, leprosy nasal smears, urine microscopy.
Skin biopsies
Two skin biopsies were taken:
• Sample 1: Summary of findings:
Skinshowingextravasationoferythrocytesintheupper
dermis. Deeper down there is a panniculitis, mainly of
lobular type. The inflammation consists of histiocytic
cells, lymphocytes, and granulocytes. There is a large
vessel with thickened muscular wall containing
granulocytes and lymphocytes. Picture of panniculitis
with vasculitis.
• Sample 2: Summary of findings:
Skin fragment shows rather normal epidermis. Upper
dermis shows extravasation of erythrocytes. Capillary
blood vessels show sometimes thickened walls, con-
taining leukocytes. Picture consistent with leucocyto-
clastic vasculitis.
Other biopsies
Other biopsies taken and found to be negative/normal
were:
• Bilateral temporal artery biopsies
• Conjuctival biopsy
• Liver biopsy
• Bronchoscopy and bronchoscopic samples
Bone marrow aspirate/biopsy: Unsuccessful initial at-
tempt. Patient declined a repeat.
Clinical course
The patient was empirically treated with broad spectrum
antibiotics, anti-malarial therapy followed by treatment
for tuberculosis and brucellosis, without improvement.
Treatment with oral prednisolone 60 mg a day resulted
in prompt improvement in his well-being, subsidence of
his fever and normalization of his ESR.
Over the subsequent years, he was maintained on pred-
nisolonetherapy.However,itbecameapparentthatredu-
cing his prednisolone dose or non-compliance on the
patient’s part resulted in the prompt recurrence of his
painful nodular skin lesions, fever, arthralgia, urticarial
facial swellings, lung infiltrates (pneumonitis), and in-
crease in both C-reactive protein and ESR (above 100
mm/hr). His general condition usually worsened during
theseepisodes,resultinginfrequenthospitaladmissions.
Unfortunately,highdoseprednisoloneledtothedevelop-
ment of diabetes mellitus which necessitated using oral
hypoglycemic agents. A brief trial of azathioprine as a
steroid-sparing agent worsened his anemia and it was
discontinued.
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myelodysplasia but with no cytogenetic abnormalities.
Over the years, in addition to myelodysplasia, he was
givenvariousdiagnosesincludingBehcet'sdisease,anti-
phospholipid syndrome, and pyrexia of unknown origin
responsive to steroids.
Drugs the patient was on at admission
These included warfarin for two previous confirmed
episodes of deep venous thrombosis (left leg and right
leg),glibenclamidefordiabetesmellitusandprednisolone
10 mg per day.
Examination and investigations on his
current presentation
Examination
He looked ill and pale. He had an urticarial right peri-or-
bital swelling as well as several tender 0.5–1.0 cm sub-
cutaneous nodules felt over the extensor and flexor sur-
faces of both upper and lower limbs. There was no lymph
node enlargement and no oral, respiratory, cardiovascu-
lar, abdominal, neurological, musculoskeletal or genital
abnormalities.
Laboratory results
Hemoglobin 9.1, MCV 101.3, WBC 9.9, platelets 152,
ESR 133, CRP 103, international normalized ratio (INR)
3.1.
Renal and liver function and urinalysis were normal.
Chest X-ray – normal.
Electrocardiogram – normal.
Management
The patient was given intravenous hydrocortisone 100
mg three times a day with a quick resolution of his
symptoms and disappearance of his painful skin swell-
ings. Within few weeks his ESR dropped to 33 mm/hr.
On reducing his steroid dose to 10 mg per day of pred-
nisolone, his facial urticaria recurred and he developed
a left sided pleuritic chest pain. A chest radiograph con-
firmed a new left basal infiltrate and an associated small
effusion.Theseagainpromptlyresolved(within48hours)
on increasing his steroid dose. Cyclosporin was then ad-
ded as a possible steroid-sparing agent.
Bone marrow examination
A repeat bone marrow examination was performed.
Salient features of bone marrow aspirate: multilineage
dysplasia involving the granulocytic, erythroid and
megakaryocytic cell lines.
Erythroiddysplasticfeaturesincluding:increasedmitosis,
nuclear lobulation and extensive vacuolation.
Myeloid dysplastic features were found in at least 19%
oftheprecursors.ThesefeaturesincludedpseudoPelger-
Huet anomaly, misshapen nuclei and increased vacuola-
tion. Blasts made up about 2% of all nucleated cells.
Normal amounts of stainable iron were present with
normal numbers of sideroblasts. Pathologically ringed
sideroblasts were not present.
Bone marrow core biopsy
Salient features of bone marrow core biopsy:
Pronounced hypercellularity (98–100%). The tri-lineage
dysplasia was confirmed; the presence of micromegaka-
ryocytes, the megalobastoid erythropoiesis and the
presence of numerous mitotic figures. Especially note-
worthywastheabnormallocalizationofimmaturemyeloid
precursors (ALIP). Lymphocytes and plasma cells were
normal. Reticulin fibrosis was mildly increased and
thinned-out bony trabeculae confirmed osteoporosis.
Abnormal non-haemopoietic cells and/or granulomata
were not present.
Discussion
The bone marrow findings were consistent with a mye-
lodysplastic syndrome best classified as Refractory
Cyctopenia with Multilineage Dysplasia (RCMD) The
presenceofALIPisanegativeprognosticfeaturealthough
the low number of myeloblasts is prognostically favour-
able [2]. Cytogenetic studies were not available and this
seriouslyhamperedfurthercharacterizationandprognos-
tication [2] in this patient. A primary myelodysplastic
syndrome is favoured over myelodysplasia secondary to
azathioprine because dysplastic features preceded aza-
thioprine exposure. We based our conclusion on the
presenceofabnormalovalmacrocyticredcells,persistent
and worsening anemia and recurrent thrombocytopenia
(counts as low as 67,000/cmm were documented with
no clear precipitant); abnormalities that were evident on
hisserialbloodcountsevenbeforetheazathioprinetrial.
Thepatienthasbeenveryhealthypriortohispresentation
anddeniedexposuretoanychemicalsorcytotoxicdrugs.
Presumably he suffers from a “benign” form of primary
myelodysplasia considering that he has had it for more
than four years so far and has still not developed any life
threatening cytopenia. Cytogenetic analysis of the bone
marrow would have been helpful to support a primary
myelodysplastic syndrome by confirming the absence of
multiple and/or complex cytogenetic abnormalities [2].
Although not all patients with MDS will exhibit genetic
abnormalities, three types of gene mutations are noted
in this illness [5]: (1) tyrosine kinase–RAS/BRAF signal
transductionpathwaygenesactivatingmutations,leading
to increased cell proliferation (Class I mutations); (2)
hematopoietic transcription factors genes inactivating
mutationsresultingindisturbedcelldifferentiation(Class
IImutations);and(3)inactivatingmutationsofthetumor
suppressor gene p53. These mutations are associated
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materialdeletion,gainortranslocationandareanessen-
tial component in disease pathogenesis, classification
and therapy [5], [6]. Patients with de novo MDS in con-
trast to therapy-related MDS are more likely to have a
normalkaryotype(50–60%versus5–10%)andlesslikely
to have unbalanced chromosome 5 or 7 aberrations
(15–25% versus 50–70%) [5].
The protean nature of this patient’s signs and symptoms
coupled with the complex clinical history made it difficult
to find a unifying underlying diagnosis. Myelodysplastic
syndrome (MDS) is that underlying pathology to explain
the immunological steroid-responsive disease in this pa-
tient.TheassociationbetweenMDSandclinicalimmune
dysfunctioniswellrecognized[3],[4].Ourpatientshowed
a relapsing-remitting disease pattern typical of auto-
immunediseaseparticularlyontaperingdownhisimmu-
nosuppressive therapy. Multiple organ systems were in-
volved including skin, lung parenchyma and serous cav-
ities. In a series of 221 cases, 30 patients (14 percent)
experienced autoimmune phenomenon of whom 7 pa-
tientshadanacutesystemicillnesswithfever,cutaneous
vasculitis, arthritis and pulmonary infiltrate [7] – a syn-
drome similar to that of our patient. Other autoimmune
associations of the myelodysplastic syndrome include
pericarditis, pleural effusions, skin ulcerations, iritis, my-
ositis, glomerulonephritis and peripheral neuropathy.
Furthermore specific autoimmune diseases have also
beenreportedincludingrelapsingpolychondritis,polymy-
algia rheumatica, Raynaud phenomenon and Sjögren's
syndrome, inflammatory bowel disease, pyoderma gan-
grenosum and Sweet's syndrome [7], [8], [9]. The patho-
physiology of these autoimmune phenomena is not well
understood.Organspecificaswellasimmune-complexes
andgenericauto-antibodies(apartfromantinuclearanti-
bodies in a minority of patients) are classically undetect-
able[8].Abroaddisturbanceofself-recognitionmechan-
isms seems to be a general feature of patients with MDS
[10]. A deficiency in the regulation of self-reactivity may
thus contribute to the disease pathogenesis [10]. Fortu-
nately, these so-called paraneoplastic autoimmune
complications mostly respond to immunosuppressive
agents (steroids, cyclosporin) with the occasionally non-
responsive syndromes contributing to early patient mor-
tality[7],[8],[9].Themanagementofthemyelodysplastic
syndrome is otherwise supportive with transfusions with
packed red blood cells and platelets, as needed, and
antibiotics for infective complications. However, newer
approaches such as growth factor therapy (recombinant
human granulocyte colony-stimulating factor (G-CSF), re-
combinant human granulocyte-macrophage colony-stim-
ulating factor (GM-CSF), and recombinant human eryth-
ropoietin-EPO), interleukin-11 therapy, thalidomide, tu-
mour necrosis factor inhibitors (infliximab), cytotoxic
agents (for blastic/acute myeloid leukaemia transforma-
tion) and bone marrow transplantation may be tried in
selected patients [11], [12], [13], [14], [15]. In the mye-
lodysplasticsyndrome,DNAmethylationcurtailssuppres-
sor genes (p53 tumour suppressor gene) activity and in-
crease the risk for acute myeloid leukaemia transforma-
tion. Use of powerful DNA hypomethylating pyrimidine
analogue azacytidine and other recently FDA approved
agent, decitabine, may reduce hypermethylation and in-
duce re-expression of key tumor suppressor genes in
myelodysplastic syndrome thus improving the long-term
prognosis [15].
Notes
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